Results 181 to 190 of about 1,395,710 (388)
Recent Advances in mRNA Delivery Systems for Cancer Therapy
Advanced Science, EarlyView.This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang +9 more
wiley +1 more source
Nature CommunicationsLymphoplasmacytic lymphoma (LPL) is an incurable low-grade lymphoma with no standard therapy. Nine asymptomatic patients treated with a first-in-human, neoantigen DNA vaccine experienced no dose limiting toxicities (primary endpoint, NCT01209871).
Szymon J. Szymura +18 more
doaj +1 more source
A study of malignant lymphomas and leukemias. V. Lymphogenous leukemia and infectious mononucleosis: The lymphatics in benign and malignant lymphoproliferative diseases [PDF]
, 1962 Gil M. Goldberg
openalex +1 more source
Advanced Microfluidics for Single Cell‐Based Cancer Research
Advanced Science, EarlyView.Cutting‐edge microfluidic platforms are transforming single‐cell cancer research. This review highlights advanced technologies, from droplet microfluidics to tumour‐chips, that enable functional and spatial single‐cell analyses. By integrating biosensing, immune components, and patient‐derived materials, these systems offer new insights into tumour ...
Adriana Carneiro +10 more
wiley +1 more source
P837: MULTIPLE MYELOMA AND ADJACENT NK CELLS CAN EXPRESS THE MACHINERY TO INTEGRATE NEURONAL SIGNALS
HemaSphere, 2023 Ana Filipa Barahona +7 more
doaj +1 more source
Intracranial Manifestations of Malignant Lymphoma
, 1955 H T John, J. D. N. Nabarro
openalex +2 more sources
Advanced Science, EarlyView.This study identifies a super‐enhancer‐driven transcriptional regulatory circuit comprising BCL6, SMAD3, and NFIB that cooperate to drive cholesterol synthesis via SREBF2/HMGCR/FDFT1 activation and regulate CDK2/CCND3 for cell cycle control. Targeting this circuit with BI‐3802 or downstream inhibitors (Fatostatin/Lovastatin) overcomes abiraterone ...
Liling Jiang +18 more
wiley +1 more source
Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure
Frontiers in OncologyBackground and aimsPatients with relapsed/refractory aggressive B-cell lymphoma(r/r aBCL)who progressed after CD19-specific chimeric antigen receptor T-cell therapy (CD19CART) had a poor prognosis.
Fei Xue +13 more
doaj +1 more source